<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23952">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794948</url>
  </required_header>
  <id_info>
    <org_study_id>YN2014TS06</org_study_id>
    <nct_id>NCT02794948</nct_id>
  </id_info>
  <brief_title>Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency</brief_title>
  <official_title>Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency:Randomized, Double-blind, DHEA-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is providing valuable traditional chinese medicine theory and
      formula in treating Primary Ovarian insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary ovarian insufficiency is a problem that is to be solved urgently in the field of
      reproductive endocrine. According to the basic theory of traditional Chinese Medicine and
      clinical experience, investigators developed a Chinese medicine formula(Hu yang yang
      kun,Hyyk). This research is designed according to the principle of randomized double blind
      control and evaluated the effectiveness and safety of Hyyk, hope to provide a kind of
      effective medicine in treating primary ovarian insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Mullerian hormone</measure>
    <time_frame>1year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follicle stimulating hormone</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estrogen</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menopause rating scale</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Cycle</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <arm_group>
    <arm_group_label>Chinese Medicine intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Western intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chinese medicine granules (HuYang Yang Kun Formula)</intervention_name>
    <description>Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &amp;pharmaceutical limited company in Jiangsu province</description>
    <arm_group_label>Chinese Medicine intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dehydroepiandrosterone</intervention_name>
    <description>The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &amp;pharmaceutical limited company in Jiangsu province.</description>
    <arm_group_label>Western intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-40

          2. Menstrual cycle change more than 7 days at least 2 times,amenorrhea less than 6
             months.

          3. Sex hormone:bFSH&gt;10u/L;or E2&gt;80pg/ml.

          4. AMH&lt;1ng/ml.

          5. Informed consent and truthfully answer the question.

        Exclusion Criteria:

          1. Dose not meet the inclusion criteria.

          2. Genital tract malformation,congenital germinal aplasia, uterine amenorrhea and so on
             organic disease.

          3. Endocrine diseases such Polycystic ovary syndrome、hyperprolactinemia 、dysfunctional
             uterine bleeding、low gonadotropin menstrual disorders and hyperthyreosis

          4. Autoimmune disease patients:Hashimoto's thyroiditis,SLE,Primary chronic adrenal
             cortical insufficiency,Asthenic bulbar paralysis,Arthritis deformans,Idiopathic
             thrombocytopenic purpura, type I diabetes and so on.

          5. Someone who have the following gynecological operation history:
             oophorocystectomy,ovarian drilling,wedgeshaped oophorectomy,adnexectomy,tubal
             resection,ligation of oviduct,pelvic abscess surgery,uterine arterial embolization.

          6. Someone who have used reproductive toxicity drugs: tripterygium
             wilfordii,tripterygium hypoglaucum hutch,chemotherapeutics and so on.

          7. A family history of ovarian failure.

          8. Have receive hormone therapy in recent 3 months.

          9. Pregnant or lactating women.

         10. with serious heart,liver and kidney disease

         11. With severe psychiatric disorders .

         12. Have participated in other clinical trials in 3 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyan Yang, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Guangzhou University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongyan Yang, professor</last_name>
    <phone>008613662465058</phone>
    <email>yanghongyan@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Peng, master</last_name>
    <phone>008618898606540</phone>
    <email>377594003@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou University of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyan Yang, professor</last_name>
      <phone>0086008613662465058</phone>
      <email>yanghongyan@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiao Peng, Master</last_name>
      <phone>18898606540</phone>
      <email>377594003@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 8, 2016</lastchanged_date>
  <firstreceived_date>March 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary ovarian insufficiency</keyword>
  <keyword>TCM intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
